HIT Consultant January 14, 2025
What You Should Know:
– Lantheus Holdings, Inc. (NASDAQ: LNTH), a leading radiopharmaceutical company, announced a definitive agreement to acquire Life Molecular Imaging Ltd. for $350M upfront and up to an additional $400M in potential earn-out and milestone payments.
– The strategic acquisition strengthens Lantheus’ position in the radiopharmaceutical market and establishes a commercial presence in the Alzheimer’s disease (AD) space.
Life Molecular Imaging Background
Life Molecular Imaging, a subsidiary of Life Healthcare Group Holdings Ltd, is dedicated to developing innovative Positron Emission Tomography (PET) radiopharmaceutical diagnostics. The acquisition brings several key assets to Lantheus, including Neuraceq® (florbetaben F18 injection), a globally approved diagnostic agent for PET imaging of the brain to estimate β-amyloid neuritic plaque density in...
Today's Sponsors
Today's Sponsor